Wednesday, January 29, 2020
Hanmi Pharmaceutical Makes Presentation on 2 Bio-drug Candidates at EASD
Drug Platform Technology
Hanmi Pharmaceutical Makes Presentation on 2 Bio-drug Candidates at EASD
  • By Choi Mun-hee
  • September 15, 2017, 03:00
Share articles

Hanmi Pharmaceuticals Principal Research Center Director Choi In-young announces the results of LAPSTriple Agonist studies at the 53rd EASD. (photo courtesy: Hanmi Pharmaceutical)
Hanmi Pharmaceuticals Principal Research Center Director Choi In-young announces the results of LAPSTriple Agonist studies at the 53rd EASD. (photo courtesy: Hanmi Pharmaceutical)

 

Hanmi Pharmaceutical Co. announced on September 14 that the two biomedicine candidates using its Acting Protein/Peptide Discovery (LAPSCOVERY) platform technology confirmed the possibility as the treatment for rare diseases through animal testing.

LAPSCOVERY is Hanmi’s own platform technology that prolongs the residence time of a biologic in order to minimize the frequency of treatment and the dose required.

The two biomedicine candidates are “LAPSTriple Agonist” and “Laps Glucagon Analog.” The lab results were announced at the European Association for the Study of Diabetes (EASD) held in Lisbon, Portugal, from the 11th to the 15th.

According to Hanmi Pharmaceutical, LAPSTriple Agonist was proved to be a potential candidate for the treatment of nonalcoholic fatty liver diseases, hepatic fibrosis and degenerative brain diseases which currently has no cure, including Parkinson's, at animal experiments.

Laps Glucagon Analog was proved to continuously raise blood sugar levels at animal experiments. Based on the result, Hanmi Pharmaceutical is planning to develop Laps Glucagon Analog as the treatment of congenital hyperinsulinemia for once-weekly use.